-
Markets
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Commodities
- Overview
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Thor Medical completes Herøya pilot facilities and initiates commissioning
26 Sep 2024 08:00 CEST
Issuer
Thor Medical ASA
26.9.2024 08:00:00 CEST | Thor Medical ASA | Non-regulatory press releases
Oslo, 26 September 2024: Thor Medical ASA, a leading emerging supplier of
alpha-emitters for next-generation precision cancer treatment, has today reached
mechanical completion of the Herøya pilot production facilities and initiated
commissioning.
"The construction of the pilot facilities has been completed on time and budget,
and with raw materials already in place at Herøya we are on track to begin
production in October and deliver the first product samples to customers before
the end of the year. This marks an important milestone as we move forward
towards commercial operations.", says Jasper Kurth, CEO of Thor Medical.
The pilot facilities will be used to verify production processes and product
quality and produce product samples for customer validation, and will also serve
as a platform for a scale-up to commercial production.
Thor Medical already has a concept study ongoing for the next phase of
commercial-scale production, with an investment decision expected by the end of
the first quarter 2025.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.
CONTACTS
* Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.no
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visitwww.thormedical.no - https://www.thormedical.no.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18254384/5032/Download%20announce
ment%20as%20PDF.pdf
More information:
Access the news on Oslo Bors NewsWeb site
Source
Thor Medical ASA
Provider
Oslo Børs Newspoint
Company Name
THOR MEDICAL ASA
ISIN
NO0010597883
Symbol
TRMED
Market
Euronext Oslo Børs